Compounds > pyrazines
Page last updated: 2024-08-21

pyrazines and cc-223

pyrazines has been researched along with cc-223 in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's8 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Apuy, J; Bissonette, R; Canan, SS; Cathers, BE; Fultz, KE; Gamez, JC; Ghoreishi, K; Hickman, M; Khambatta, G; Leisten, J; Moghaddam, MF; Mortensen, DS; Narla, RK; Packard, G; Peng, SX; Perrin-Ninkovic, S; Raymon, HK; Richardson, S; Sankar, S; Shi, T; Tong, Z; Tran, T; Worland, P; Xu, S; Xu, W; Yang, WQ; Zhao, J1
Apuy, J; Bahmanyar, S; Bisonette, RR; Canan, SS; Cathers, BE; Correa, M; Elsner, J; Fultz, KE; Gamez, JC; Harris, R; Hickman, M; Khambatta, G; Lee, BG; Leisten, J; Moghaddam, MF; Mortensen, DS; Narla, RK; Packard, G; Papa, P; Parnes, JS; Peng, SX; Perrin-Ninkovic, SM; Raymon, HK; Richardson, SJ; Riggs, JR; Sankar, S; Sapienza, J; Shevlin, G; Tehrani, L; Whitefield, B; Worland, P; Zhao, J1
Chen, D; Liu, M; Qiu, C; Sun, K; Wang, J; Xie, Z1
Anthony, LB; Carreira, VS; Chu, Z; Dahche, HM; Jiang, M; Koch, SE; Komurov, K; LaSance, K; Mercer, CA; Orr-Asman, MA; Plas, DR; Qi, X; Rubinstein, J; Thomas, HE; Worley, M1
Atsriku, C; Li, Y; Nissel, J; Surapaneni, S; Tong, Z; Wang, X; Yerramilli, U1
Atsriku, C; Li, Y; Liu, H; Narayanan, R; Nissel, J; Surapaneni, S; Tong, Z; Wang, X1
Jin, X; Li, XF; Wang, JY; Zhang, X1
Bendell, J; de Haan, H; Filvaroff, EH; Hege, K; Li, S; Mahipal, A; Meyer, T; Mita, A; Mita, M; Munster, PN; Nemunaitis, J; Paz-Ares, L; Wolin, E1

Trials

1 trial(s) available for pyrazines and cc-223

ArticleYear
A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms.
    PloS one, 2019, Volume: 14, Issue:9

    Topics: Administration, Oral; Adult; Aged; Carcinoid Tumor; Cohort Studies; Female; Gastrointestinal Neoplasms; Humans; Male; Maximum Tolerated Dose; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Middle Aged; Neuroendocrine Tumors; Pyrazines

2019

Other Studies

7 other study(ies) available for pyrazines and cc-223

ArticleYear
CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization.
    Molecular cancer therapeutics, 2015, Volume: 14, Issue:6

    Topics: Animals; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Female; HCT116 Cells; HEK293 Cells; Humans; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice, SCID; Molecular Structure; Multiprotein Complexes; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrazines; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays

2015
Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223.
    Journal of medicinal chemistry, 2015, Jul-09, Volume: 58, Issue:13

    Topics: Animals; Antineoplastic Agents; Drug Discovery; Humans; Male; Models, Molecular; Molecular Structure; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyrazines; Rats; Signal Transduction; Structure-Activity Relationship; TOR Serine-Threonine Kinases; Tumor Cells, Cultured

2015
CC-223 blocks mTORC1/C2 activation and inhibits human hepatocellular carcinoma cells in vitro and in vivo.
    PloS one, 2017, Volume: 12, Issue:3

    Topics: Aged; Animals; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Caspase 9; Cell Line, Tumor; Cell Proliferation; Hep G2 Cells; Humans; Liver Neoplasms; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice; Mice, SCID; Middle Aged; Mitochondria; Multiprotein Complexes; Protein Kinase Inhibitors; Pyrazines; Reactive Oxygen Species; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2017
mTOR Kinase Inhibition Effectively Decreases Progression of a Subset of Neuroendocrine Tumors that Progress on Rapalog Therapy and Delays Cardiac Impairment.
    Molecular cancer therapeutics, 2017, Volume: 16, Issue:11

    Topics: Animals; Carcinoid Heart Disease; Cell Line, Tumor; Drug Resistance, Neoplasm; Everolimus; Gene Expression Regulation, Neoplastic; Humans; Mice; Neuroendocrine Tumors; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrazines; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2017
Absorption, distribution, metabolism, and excretion of mTOR kinase inhibitor CC-223 in rats, dogs, and humans.
    Xenobiotica; the fate of foreign compounds in biological systems, 2019, Volume: 49, Issue:1

    Topics: Administration, Oral; Animals; Body Fluids; Dogs; Humans; Pyrazines; Rats; TOR Serine-Threonine Kinases

2019
Assessment of drug-drug interaction potential and PBPK modeling of CC-223, a potent inhibitor of the mammalian target of rapamycin kinase.
    Xenobiotica; the fate of foreign compounds in biological systems, 2019, Volume: 49, Issue:1

    Topics: Animals; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Ketoconazole; Membrane Transport Proteins; Microsomes, Liver; Prospective Studies; Pyrazines; Sirolimus; TOR Serine-Threonine Kinases

2019
CC-223 inhibits human head and neck squamous cell carcinoma cell growth.
    Biochemical and biophysical research communications, 2018, 02-19, Volume: 496, Issue:4

    Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Head and Neck Neoplasms; Humans; Protein Kinase Inhibitors; Pyrazines; Squamous Cell Carcinoma of Head and Neck; TOR Serine-Threonine Kinases; Treatment Outcome

2018